ADVANCED SOLID TUMORS CANCER
Clinical trials for ADVANCED SOLID TUMORS CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS CANCER trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New daily pill aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental daily pill, NDI-219216, in about 134 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take the pill daily, visit the …
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated May 16, 2026 23:32 UTC
-
New drug PQ203 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests the safety and best dose of a new drug called PQ203 in people with advanced solid tumors, including triple-negative breast cancer. About 80 participants whose cancer has progressed after standard treatments will receive the drug. The goal is to find a…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters human trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New drug ORB-021 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests whether the investigational drug ORB-021 is safe and tolerable in 36 adults with advanced solid tumors that have not responded to standard treatments. Researchers will also find the best dose for future studies. Participants will go through screening,…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated May 04, 2026 16:30 UTC
-
Live tumor samples could unlock secrets of immunotherapy success
Knowledge-focused Recruiting nowThis study collects live tumor tissue from 2,000 people with various cancers to understand why some respond to immunotherapy and others don't. Participants give a biopsy as part of their normal care, and researchers analyze the samples in the lab. The goal is to develop better wa…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Sponsor: Elephas • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC